MyMD is a clinical-stage pharmaceutical company focused on the development of drug products that represent a transformation in the targeting of aging and age-related diseases; autoimmune diseases; and chronic pain, anxiety and sleep disorders. Our team has partnered with academic founders and key opinion leaders to identify synthetic therapeutics, including the first drug being designed to significantly increase human lifespan.
MyMD is commercializing two broad drug platforms, each with its own distinct indications. MYMD-1 is a novel therapeutic shown to positively impact multiple conditions related to immunometabolic dysregulation. SUPERA-1R is a synthetic cannabidiol that offers better bioavailability and potency than botanicals. Both are protected by a robust, worldwide patent portfolio.
MYMD-1 is a clinical-stage, synthetic plant alkaloid that has been shown to ameliorate immunometabolic dysregulation targeting immune cell metabolism. Its mechanism of action and efficacy in autoimmune diseases, such as Multiple Sclerosis EAE (MS) and thyroiditis, and aging mouse models have been studied through MyMD’s collaboration with several academic institutions.
Regulates the immuno-metabolic system through the modulation of numerous pro-inflammatory cytokines, including TNF-α, IL-6 and IL-17A. MYMD-1 is also not detrimental to cell viability and is small enough to cross the blood-brain barrier.
MYMD-1 is being developed to target aging (sarcopenia) and depression in age or inflammatory-related diseases.
SUPERA-1R is a synthetic, preclinical cannabidiol derivative that has demonstrated to effectively target CB2 receptors. As a new molecular entity (patent pending), SUPERA-1R addresses the unmet need for a synthetic CBD with enhanced bioavailability and potency so physicians may treat patients with an FDA approved drug rather than botanicals that contain impurities.
Approximately 7-8X more effective than plant-derived CBD in reducing MAO-A and MAO-B (which play a role in substance addiction) in a dose-dependent manner. It has been shown to inhibit opioid receptors and is more potent than plant-based CBD in binding to CB2 receptors.
SUPERA-1R is being developed to address anxiety, chronic pain, and seizures and is expected to begin human trials as a therapy for epilepsy, followed by chronic pain.
Founding Director of the Medical Affairs, Drug Safety and Medical Writing Departments, Quintiles
Founder and CEO, Chapman Pharmaceutical Consulting, Inc.
Prior Founder and Chief, Neuropsychiatric CNS Autoimmune Consultation Clinic, Johns Hopkins Multiple Sclerosis Center of Excellence, and Founder and Clinical Director, Johns Hopkins Psychiatric Esketamine Clinic
Adjunct Faculty, Departments of Psychiatry and Neurology
Johns Hopkins University School of Medicine
Shareholder, Banner & Witcoff
Patent Examiner, U.S. Patent and Trademark Office (1992-1998)
Please complete the form below and click submit
Akers Biosciences Business Update
On Wednesday, November 18, 2020, the companies held a video conference for investors to provide additional context on the integrated company, the clinical pipeline and drug development plan, and the commercial potential of the targeted indications. To view the recorded conference, please use the following link.